MARKET

INTS

INTS

INTENSITY THERAPEUTICS INC
NASDAQ
4.250
-0.020
-0.47%
After Hours: 4.250 0 0.00% 19:30 08/28 EDT
OPEN
4.300
PREV CLOSE
4.270
HIGH
4.579
LOW
4.220
VOLUME
22.42K
TURNOVER
--
52 WEEK HIGH
43.50
52 WEEK LOW
3.510
MARKET CAP
13.88M
P/E (TTM)
-0.8616
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INTS last week (0817-0821)?
Weekly Report · 5d ago
Intensity Therapeutics Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 08/18 17:49
Intensity Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/18 17:49
HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7
Benzinga · 08/18 17:40
Weekly Report: what happened at INTS last week (0810-0814)?
Weekly Report · 08/17 09:02
Intensity Therapeutics price target lowered to $15 from $30 at Alliance Global
TipRanks · 08/11 19:55
Intensity Therapeutics Q2 EPS $(1.11), Inline
Benzinga · 08/11 11:52
Intensity Therapeutics GAAP EPS of -$1.11 misses by $0.14
Seeking Alpha · 08/11 11:35
More
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Webull offers Intensity Therapeutics Inc stock information, including NASDAQ: INTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INTS stock methods without spending real money on the virtual paper trading platform.